Simes, R.J.

patient trial treatment infarction /iiia study glycoprotein death ratio mortality group analysis therapy inhibitor survival difference outcome syndrome table effect 30 days randomized arrhythmia streptokinase reduction cost-effectiveness treatment effect placebo elevation event baseline 1·00 30- result intervention investigator troponin heart cost-effectiveness ratio hospital heparin t-pa group disease fi rst year platelet signi stroke signi ficantly characteristic 180 days lancet publishing group revascularisation percent pursuit concentration angioplasty estimate baseline characteristics end points lancet gusto life expectancy risk reduction university gusto study model thrombolytic infusion trial-specific odds ratios value cardiol thrombolytic therapy point england journal tissue plasminogen activator in-hospital m l simoons st-segment month non-st-segment elevation acs